FDA Inspection 1010372 — Tedor Pharma, Inc.

Tedor Pharma, Inc. — FEI 3003855180

The FDA completed an inspection of Tedor Pharma, Inc. on April 20, 2017 in Cumberland, RI. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 4 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
April 20, 2017
Fiscal Year
2017
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Cumberland, RI (United States)

Citations

IDCFRDescription
145021 CFR 211.113(a)Procedures for non-sterile drug products
202821 CFR 211.192Extent of discrepancy, failure investigations
220521 CFR 211.186(b)(9)Manufacturing Instructions and Specifications
439121 CFR 211.180(e)(2)Items to cover on annual reviews